OBJECTIVE: To systematically evaluate the efficacy and safety of ticagrelor combined with rosuvastatin in the treatment of unstable angina pectoris（UAP）. METHODS: PubMed

the Cochrane Library

Embase

CNKI

Wanfang Data and VIP database were electronically retrieved to collect clinical randomized controlled trial（RCT） of ticagrelor combined with rosuvastatin in the treatment of unstable angina pectoris（on the basis of conventional treatment

the study group was treated with ticagrelor combined with rosuvastatin

while the control group received clopidogrel combined with rosuvastatin）

the retrieval time limit is from the establishment of the database to Sept. 2020. According to the inclusion and exclusion criteria

literature were selected

data were extracted and quality was evaluated. RevMan 5.3 software was used for Meta-analysis. RESULTS: Totally 12 RCT were enrolled

including 1 220 patients. Meta-analysis showed that compared with clopidogrel combined with rosuvastatin

ticagrelor combined with rosuvastatin could significantly improve the total clinical effective rate（RR=1.26

95%CI=1.19-1.33

P<0.000 01） and the level of high density lipoprotein cholesterol（MD=0.43

95%CI=0.23-0.63

P<0.000 1）

decrease the total cholesterol level（MD=-0.92

95%CI=-1.12--0.72

P<0.000 01）

triglyceride level（MD=-0.75

95%CI=-0.89--0.61

P<0.000 01）

low density lipoprotein cholesterol level（MD=-0.85

95%CI=-1.06--0.65

P<0.000 01） and high sensitivity C-reactive protein（MD=-2.33

95%CI=-2.75--1.90

P<0.000 01）

decrease the frequency of angina pectoris（MD=-2.94

95%CI=-3.47--2.40

P<0.000 01）

shorten the duration of angina pectoris（SMD=-2.35

95%CI=-3.35--1.35

P<0.000 01）

with statistically significant differences. There was no statistically significant difference in the incidence of adverse drug reactions between two groups（RR=0.59

95%CI=0.33-1.04

P=0.07）. CONCLUSIONS: Current evidence shows that ticagrelor combined with rosuvastatin in the treatment of UAP is significantly better than clopidogrel combined with rosuvastatin in terms of total effective rate and various clinical indicators

and the safety is similar to that of clopidogrel combined with rosuvastatin.